SLC5A2 and heart failure: Angiotensin receptor blockers with neprilysin inhibitors (ARNI) and sodium-glucose transport 2 inhibitors (SGLT2 inhibitors) are the new addition to the armamentarium of heart failure drugs, making heart failure therapy’s four pillars (Ndiaye et al., 2023).